Ligand Pharmaceuticals
Ligand Pharmaceuticals

Ligand Pharmaceuticals

Biotechnology
WebsiteInvestor RelationsSEC
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

$6.2B

Market Cap • 11/13/2026

1987

(39 years)

Founded

1994

(32 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

6,4

P/S

24,3

P/EBITDA

104,7

P/OCF

67,9

P/FCF

68,2

P/E

137,9

BVPS

48,1

EPS

2,5

Market Cap

Market Cap

6,2B

EV

6,9B

EV/Revenue

27,1

EV/EBITDA

116,6

EV/EBIT

286,3

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

0,8%

Total Yield

0,8%

Payout

0%

Retained Earnings

554,8M

Profitability

Gross Margin

95,2%

EBITDA Margin

23,2%

EBIT Margin

9,5%

Net Margin

20,3%

D&A/EBITDA

58,5%

R&D/Revenue

9,1%

Capex/Revenue

0,2%

Capex/D&A

1,2%

Capex/OCF

0,4%

SBC/OCF

62,3%

% PPE

0%

% Goodwill

9,3%

ROE

5,4%

ROIC

1,6%

Growth

CAGR Revenue 5Y

-1,6%

CAGR Op. Income 5Y

-16,6%

CAGR Net Income 5Y

-5,5%

CAGR EPS 5Y

-10,9%

CAGR OCF 5Y

23,5%

Leverage

N.D./EBITDA

12

Debt/Equity

0%

Current Ratio

1,2

Quick Ratio

1,1

Interest Coverage

294%

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium